enkephalin, leucine has been researched along with Parkinsonian Disorders in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.96) | 18.2507 |
| 2000's | 39 (76.47) | 29.6817 |
| 2010's | 10 (19.61) | 24.3611 |
| 2020's | 1 (1.96) | 2.80 |
| Authors | Studies |
|---|---|
| Andrén, PE; Bezard, E; Fridjonsdottir, E; Gunnarsdottir, H; Hulme, H; Nilsson, A; Shariatgorji, R; Svenningsson, P; Vallianatou, T; Wadensten, H; Zhang, X | 1 |
| Hoshino, N; Ishikawa, T; Muraoka, S; Nishimura, T; Okano, M; Satoyoshi, H; Takahata, K; Tsunekawa, H | 1 |
| Avnor, Y; Bishop, C; Chambers, NE; Conti, MM; Gross, L; Lanza, K; Meadows, SM; Ostock, CY | 1 |
| Andrén, PE; Bezard, E; Bourdenx, M; Crossman, AR; Fälth, M; Li, Q; Nilsson, A; Wadensten, H | 1 |
| Di Paolo, T; Grégoire, L; Jourdain, VA; Morin, N; Morissette, M | 1 |
| Bezard, E; Crossman, AR; Ko, WK; Martin-Negrier, ML; Ravenscroft, P | 1 |
| Battaglia, G; Bruno, V; Bucci, D; Cannella, M; Gradini, R; Molinaro, G; Motolese, M; Nicoletti, F | 1 |
| Bonastre, M; Cortés, R; Marin, C; Mengod, G; Rodríguez-Oroz, MC | 1 |
| Aguilar, E; Cortés, R; Marin, C; Mengod, G; Obeso, JA; Rodríguez-Oroz, MC | 1 |
| Danysz, W; Dekundy, A; Quack, G; Valastro, B | 1 |
| Di Paolo, T; Morissette, M | 1 |
| Brotchie, JM; Fox, SH; Johnston, T; Millan, MJ; Reyes, G; Visanji, NP | 1 |
| Bing, G; Kim, HC; Liu, M; Nguyen, XV | 1 |
| Carboni, E; Carta, AR; Frau, L; Garau, A; Ibba, M; Schintu, N | 1 |
| Jia, J; Li, B; Liu, L; Pan, Y; Sun, Z; Wang, H; Wang, X; Yu, F; Zhang, L | 1 |
| Di Paolo, T; Grégoire, L; Lévesque, D; Morissette, M; Ouattara, B; Rouillard, C; Samadi, P; Tamim, MK | 1 |
| Dunnett, SB; Lane, EL | 1 |
| Capper-Loup, C; Frey, CM; Kaelin-Lang, A; Rebell, D | 1 |
| Björklund, A; Cenci, MA; Kirik, D; Winkler, C | 1 |
| Cenci, MA | 1 |
| Aoyama, S; Kase, H; Kobayashi, H; Koga, K; Kuwana, Y; Miyaji, H; Mori, A; Sekine, S; Uchimura, T | 1 |
| Cannizzaro, C; Jenner, P; Pearce, RK; Rose, S; Tel, BC; Zeng, BY | 1 |
| Bonastre, M; Hirsch, EC; Marin, C; Périer, C; Tolosa, E | 1 |
| Bezard, E; Bioulac, B; Dovero, S; Gross, CE; Jaber, M; Ravenscroft, P | 1 |
| Cenci, MA; Lundblad, M; Vaudano, E | 1 |
| Bentlage, C; Björklund, A; Cenci, MA; Nikkhah, G; Winkler, C | 1 |
| Bezard, E; Bioulac, B; Dovero, S; Gross, CE; Meissner, W | 1 |
| Biguet, NF; Colin, P; Guibert, B; Mallet, J; Sánchez-Capelo, A | 1 |
| Bonastre, M; Hirsch, EC; Jimenez, A; Marin, C; Périer, C; Tolosa, E | 1 |
| Landry, E; Lévesque, D; Rouillard, C; St-Hilaire, M | 1 |
| Brotchie, JM; Crossman, AR; Duty, S; Fox, SH; Henry, B | 1 |
| Brotchie, JM; Chalon, S; Crossman, AR; Ravenscroft, P | 1 |
| Betarbet, R; Greenamyre, JT | 1 |
| de Yébenes, JG; Fernández-Ruiz, J; González, S; Lastres-Becker, I; Mena, MA; Ramos, JA; Serrano, A | 1 |
| Bédard, PJ; Calon, F; Di Paolo, T; Dridi, M; Hadj Tahar, A; Meltzer, LT; Morissette, M | 1 |
| Martín, AB; Mendialdua, A; Moratalla, R; Pavón, N | 1 |
| Ariano, MA; Buchanan, TM; Collier, TJ; Elsworth, JD; Grissell, AE; Littlejohn, FC; Steece-Collier, K | 1 |
| Aguilar, E; Bové, J; Cortés, R; Marin, C; Mengod, G; Serrats, J | 1 |
| Aubert, I; Bezard, E; Bioulac, BH; Bloch, B; Crossman, AR; Dovero, S; Gross, CE; Guigoni, C; Li, Q | 1 |
| Dagostino, P; Katz, J; Soghomonian, JJ; Wang, H | 1 |
| Konieczny, J; Kuter, K; Ossowska, K; Pilc, A; Wardas, J | 1 |
| Ding, Y; Hwang, DY; Kang, UJ; Kim, KS; Restrepo, J; Won, L | 1 |
| Guan, Q; He, Y; Tan, L; Zhan, Q | 1 |
| Cheetham, S; Jenner, P; Lane, EL | 1 |
| Annalisa, P; Carta, AR; Frau, L; Lucia, F; Micaela, M; Morelli, M; Nicola, S; Nicoletta, S; Pinna, A; Pontis, S; Schintu, N; Silvia, P; Simola, N | 1 |
| Andersson, M; Cenci, MA; Hilbertson, A | 1 |
| Ganguly, A; Keefe, KA | 1 |
| Bezard, E; Brotchie, JM; Crossman, AR; Gross, CE; Ravenscroft, P | 1 |
| Carta, A; Fenu, S; Morelli, M | 1 |
| Andersson, M; Cenci, MA; Lundblad, M; Westin, JE | 1 |
| Groenewegen, HJ; Van De Witte, SV; Voorn, P | 1 |
51 other study(ies) available for enkephalin, leucine and Parkinsonian Disorders
| Article | Year |
|---|---|
Simultaneous mass spectrometry imaging of multiple neuropeptides in the brain and alterations induced by experimental parkinsonism and L-DOPA therapy.
Topics: Animals; Brain; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Globus Pallidus; Levodopa; Male; Neostriatum; Parkinsonian Disorders; Rats, Wistar | 2020 |
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Topics: Animals; Antiparkinson Agents; Benserazide; Cytoskeletal Proteins; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Movement; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger; Selegiline; Time Factors | 2018 |
Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperazines; Protein Precursors; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Time Factors; Vilazodone Hydrochloride | 2018 |
Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Enkephalins; Female; Globus Pallidus; Levodopa; Macaca mulatta; Neuropeptides; Parkinsonian Disorders; Protein Precursors; Putamen; Tachykinins | 2014 |
Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Levodopa; Macaca fascicularis; MAP Kinase Signaling System; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger | 2014 |
RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cells, Cultured; Corpus Striatum; Dyskinesia, Drug-Induced; Enkephalins; Functional Laterality; Gene Expression; Genetic Therapy; Levodopa; Male; Oligonucleotides, Antisense; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RGS Proteins; RNA, Messenger; Up-Regulation | 2014 |
Changes in the expression of genes encoding for mGlu4 and mGlu5 receptors and other regulators of the indirect pathway in acute mouse models of drug-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Catalepsy; Corpus Striatum; Enkephalins; Haloperidol; Mice, Inbred C57BL; Mice, Knockout; Neurons; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Receptor, Cannabinoid, CB1; Receptor, Metabotropic Glutamate 5; Receptors, Adenosine A2; Receptors, Metabotropic Glutamate; Time Factors; Ventral Thalamic Nuclei | 2015 |
From unilateral to bilateral parkinsonism: Effects of lateralization on dyskinesias and associated molecular mechanisms.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Functional Laterality; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger | 2015 |
Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.
Topics: Animals; Antiparkinson Agents; Apomorphine; Brain; Catechols; Corpus Striatum; Dynorphins; Electron Transport Complex IV; Enkephalins; Gene Expression; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Motor Activity; Nitriles; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; RNA, Messenger; Substantia Nigra; Subthalamus | 2008 |
Oral creatine supplementation attenuates L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Creatine; Dietary Supplements; Disease Models, Animal; Dyskinesia, Drug-Induced; Energy Metabolism; Enkephalins; Female; In Vitro Techniques; Levodopa; Neostriatum; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Phosphocreatine; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Statistics, Nonparametric | 2009 |
Effect of estradiol on striatal dopamine activity of female hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Biogenic Amines; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Enkephalins; Estradiol; Estrogens; Female; In Situ Hybridization; Iodine Radioisotopes; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Protein Precursors; RNA, Messenger | 2009 |
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzopyrans; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger | 2009 |
Effects of prodynorphin deletion on striatal dopamine in mice during normal aging and in response to MPTP.
Topics: Aging; Amino Acid Sequence; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Enkephalins; Female; Immunohistochemistry; Male; Mice; Mice, Knockout; Neural Pathways; Parkinsonian Disorders; Phosphorylation; Protein Precursors; Serine; Substantia Nigra; Tyrosine 3-Monooxygenase; Up-Regulation | 2009 |
Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Brain; CD11b Antigen; Cell Count; Chromatography, High Pressure Liquid; Disease Models, Animal; Disease Progression; Dopamine; Electrochemistry; Enkephalins; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Locomotion; Male; Mice; Mice, Inbred C57BL; Microglia; Nerve Degeneration; Olfactory Bulb; Parkinsonian Disorders; Time Factors; Tyrosine 3-Monooxygenase | 2009 |
Electro-acupuncture stimulation improves motor disorders in Parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Brain; Disease Models, Animal; Dopamine; Dyskinesias; Electroacupuncture; Enkephalins; Glutamate Decarboxylase; Male; Medial Forebrain Bundle; Motor Activity; Neurons; Parkinsonian Disorders; Random Allocation; Rats; Rats, Wistar; RNA, Messenger; Substance P; Tyrosine 3-Monooxygenase | 2009 |
Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cocaine; Corpus Striatum; Disease Models, Animal; Docosahexaenoic Acids; Dopamine; Dopamine Uptake Inhibitors; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Iodine Isotopes; Levodopa; Macaca fascicularis; Naltrexone; Neuropeptides; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Precursors; RNA, Messenger; Sulfonamides; Tachykinins; Thiazoles; Time Factors | 2010 |
Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Indoles; Levodopa; Oxidopamine; Parkinsonian Disorders; Piribedil; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotation; Time Factors | 2010 |
Adaptive gene expression changes on the healthy side of parkinsonian rats.
Topics: Adaptation, Physiological; Adrenergic Agents; Animals; Cerebral Cortex; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dynorphins; Enkephalins; Female; Functional Laterality; Gene Expression Profiling; Locomotion; Neostriatum; Nerve Tissue Proteins; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger; Tyrosine 3-Monooxygenase | 2013 |
L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
Topics: Afferent Pathways; Animals; Bacterial Proteins; Behavior, Animal; Biomarkers; Brain Mapping; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Enkephalins; Female; Image Processing, Computer-Assisted; Levodopa; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Putamen; Rats; Rats, Sprague-Dawley; RNA, Messenger; Severity of Illness Index; Substantia Nigra; Sympathectomy, Chemical; Transcription Factors | 2002 |
Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Sympatholytics; Transcription Factors | 2002 |
Distribution of adenosine A(2A) receptor antagonist KW-6002 and its effect on gene expression in the rat brain.
Topics: Administration, Oral; Adrenergic Antagonists; Animals; Carbon Radioisotopes; Corpus Striatum; Enkephalins; Gene Expression; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Purinergic P1 Receptor Antagonists; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; RNA, Messenger; Sympatholytics; Tachykinins; Tissue Distribution | 2002 |
Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Callithrix; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Enkephalins; Female; Indoles; Levodopa; Male; Mazindol; Neostriatum; Neural Pathways; Neuropeptides; Parkinsonian Disorders; Protein Precursors; Receptors, Purinergic P1; RNA, Messenger; Tachykinins | 2002 |
AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa.
Topics: Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Isoquinolines; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Tetrazoles | 2002 |
Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Binding, Competitive; Chronic Disease; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Enkephalins; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neural Pathways; Neurons; Parkinsonian Disorders; Protein Precursors; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Substantia Nigra; Tachykinins; Tyrosine 3-Monooxygenase | 2003 |
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Purinergic P1 Receptor Antagonists; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; RNA, Messenger; Treatment Outcome | 2003 |
Regulation of neuropeptide mRNA expression in the basal ganglia by intrastriatal and intranigral transplants in the rat Parkinson model.
Topics: Adrenergic Agents; Animals; Autoradiography; Basal Ganglia; Brain Mapping; Disease Models, Animal; Embryo, Mammalian; Enkephalins; Entopeduncular Nucleus; Female; Fetal Tissue Transplantation; Gene Expression Regulation; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Regression Analysis; RNA, Messenger; Septal Nuclei; Substantia Nigra; Tachykinins | 2003 |
Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Corpus Striatum; Disease Models, Animal; Disease Progression; Electron Transport Complex IV; Enkephalins; Gene Expression Regulation; In Situ Hybridization; Male; Mice; Mice, Inbred C57BL; Neuropeptides; Parkinsonian Disorders; Protein Precursors; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Tachykinins | 2003 |
Transforming growth factor beta1 overexpression in the nigrostriatal system increases the dopaminergic deficit of MPTP mice.
Topics: Animals; Disease Models, Animal; Dopamine; Down-Regulation; Enkephalins; Gene Transfer Techniques; Genetic Predisposition to Disease; Genetic Vectors; Humans; Male; Mice; Mice, Inbred C57BL; Neostriatum; Neural Pathways; Parkinsonian Disorders; RNA, Messenger; Substantia Nigra; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Cells, Cultured; Up-Regulation | 2003 |
Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Basal Ganglia; Corpus Striatum; Disease Models, Animal; Electron Transport Complex IV; Enkephalins; Entopeduncular Nucleus; Globus Pallidus; Glutamate Decarboxylase; In Situ Hybridization; Isoenzymes; Levodopa; Male; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus | 2003 |
Denervation and repeated L-DOPA induce a coordinate expression of the transcription factor NGFI-B in striatal projection pathways in hemi-parkinsonian rats.
Topics: Animals; Corpus Striatum; Denervation; DNA-Binding Proteins; Enkephalins; Gene Expression Regulation; Levodopa; Male; Neural Pathways; Nuclear Receptor Subfamily 4, Group A, Member 1; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; RNA, Messenger; Transcription Factors | 2003 |
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enkephalins; Female; Humans; Macaca mulatta; Male; Parkinson Disease; Parkinsonian Disorders; Protein Precursors; RNA, Messenger | 2003 |
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression; In Situ Hybridization; Indoles; Levodopa; Male; Motor Activity; Opioid Peptides; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Synaptic Transmission | 2004 |
Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Disease Models, Animal; Dopamine; Down-Regulation; Enkephalins; Female; Functional Laterality; Globus Pallidus; Macaca mulatta; Neostriatum; Neuropeptides; Parkinsonian Disorders; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Substance P; Substantia Nigra; Up-Regulation | 2004 |
Cannabinoid CB(1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice.
Topics: Analysis of Variance; Animals; Basal Ganglia; Disease Models, Animal; Enkephalins; Female; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Parkinsonian Disorders; Protein Precursors; Receptor, Cannabinoid, CB1; RNA, Messenger; Sex Factors; Statistics, Nonparametric; Substance P; Superoxide Dismutase; Tyrosine 3-Monooxygenase; Ubiquitin-Protein Ligases | 2005 |
Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
Topics: Animals; Antiparkinson Agents; Benserazide; Benzoxazoles; Corpus Striatum; Dopamine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Protein Precursors; Receptors, N-Methyl-D-Aspartate; RNA, Messenger | 2006 |
ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Blotting, Western; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dyskinesias; Enkephalins; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Immunohistochemistry; In Situ Hybridization; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Precursors; Proto-Oncogene Proteins c-fos; RNA, Messenger; Statistics, Nonparametric; Time Factors | 2006 |
Partial dopamine loss enhances activated caspase-3 activity: differential outcomes in striatal projection systems.
Topics: Animals; Apoptosis; Caspase 3; Caspases; Corpus Striatum; Disease Models, Animal; Disease Progression; Dopamine; Efferent Pathways; Enkephalins; Enzyme Activation; Male; Mitochondrial Proteins; Nerve Degeneration; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase; Up-Regulation | 2005 |
Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adenosine; Adrenergic Agents; Animals; Caffeine; Corpus Striatum; Dynorphins; Dyskinesias; Enkephalins; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; RNA, Messenger | 2006 |
Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Corpus Striatum; Drug Interactions; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression Regulation; In Situ Hybridization; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Protein Precursors; Radioligand Assay; Receptors, Opioid; Regression Analysis; RNA, Messenger; Subthalamic Nucleus | 2007 |
Unilateral 6-hydroxydopamine lesion of dopamine neurons and subchronic L-DOPA administration in the adult rat alters the expression of the vesicular GABA transporter in different subsets of striatal neurons and in the substantia nigra, pars reticulata.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Down-Regulation; Drug Administration Schedule; Enkephalins; Functional Laterality; gamma-Aminobutyric Acid; Gene Expression Regulation; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Synaptic Transmission; Up-Regulation; Vesicular Inhibitory Amino Acid Transport Proteins | 2007 |
The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats.
Topics: Animals; Corpus Striatum; Cyclopentanes; Dopamine Antagonists; Dose-Response Relationship, Drug; Enkephalins; Excitatory Amino Acid Agonists; Gene Expression Regulation; Glutamic Acid; Haloperidol; Male; Neural Pathways; Opioid Peptides; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate; RNA, Messenger; Substantia Nigra; Synaptic Transmission; Tricarboxylic Acids; Up-Regulation | 2007 |
Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.
Topics: Afferent Pathways; Animals; Antiparkinson Agents; Aphakia; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Mice; Mice, Inbred C57BL; Mice, Neurologic Mutants; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Substantia Nigra | 2007 |
Changes in the prodynorphin gene and DARPP-32 state in 6-OHDA-lesioned rats following long-term treatment with l-dopa.
Topics: Amino Acid Sequence; Animals; Basal Ganglia; Brain Chemistry; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Administration Schedule; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Female; Gene Expression Regulation; Levodopa; Male; Neural Pathways; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Threonine; Time | 2007 |
Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Chlorobenzenes; Corpus Striatum; Cyclobutanes; Dynorphins; Enkephalins; Gene Expression; In Situ Hybridization; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; RNA, Messenger; Substance P; Time | 2008 |
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dopamine Agonists; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Indoles; Male; Motor Activity; Neural Pathways; Opioid Peptides; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger | 2008 |
Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease.
Topics: Animals; Antisense Elements (Genetics); Bacterial Proteins; Biomarkers; Cell Count; Disease Models, Animal; Dyskinesias; Enkephalins; Female; Levodopa; Neostriatum; Nerve Degeneration; Neurons; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Transcription Factors; Ventral Tegmental Area | 1999 |
Unilateral dopamine depletion increases expression of the 2A subunit of the N-methyl-D-aspartate receptor in enkephalin-positive and enkephalin-negative neurons.
Topics: Animals; Autoradiography; Corpus Striatum; Dopamine; Enkephalins; Gene Expression; In Situ Hybridization; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Sympatholytics | 2001 |
Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Enkephalins; Female; Gene Expression Regulation; Homovanillic Acid; Macaca fascicularis; Neostriatum; Neural Pathways; Neurons; Parkinsonian Disorders; Protein Precursors; RNA, Messenger; Up-Regulation | 2001 |
Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Dopamine Agonists; Down-Regulation; Drug Interactions; Drug Tolerance; Dynorphins; Enkephalins; Gene Expression; Glutamate Decarboxylase; Isoenzymes; Levodopa; Neostriatum; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; RNA, Messenger; Sympatholytics; Up-Regulation | 2001 |
Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease.
Topics: Animals; Bromocriptine; Denervation; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Drug Administration Schedule; Enkephalins; Female; Gene Expression Regulation; Immunohistochemistry; Levodopa; Neostriatum; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sympatholytics | 2001 |
MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Dopamine Agonists; Drug Interactions; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Immunohistochemistry; Levodopa; Male; Motor Activity; Neostriatum; Neurons; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Tachykinins; Tyrosine 3-Monooxygenase | 2002 |